Management of Malignant Bowel Obstruction
All patients with malignant bowel obstruction require immediate multidisciplinary evaluation involving oncologists, surgeons, and endoscopists to determine the optimal intervention based on obstruction location, resectability, patient functional status, prognosis, and goals of care 1.
Initial Assessment Framework
The management algorithm hinges on three critical decision points:
- Location of obstruction (esophageal/gastric cardia, gastric outlet, or colonic)
- Surgical candidacy (resectable vs. non-resectable disease)
- Patient factors (life expectancy, functional status, goals of care)
Esophageal and Gastric Cardia Obstruction
For Resectable Disease
Do NOT routinely place self-expanding metal stents (SEMS) in patients who are candidates for resection or chemoradiation 1. Evidence demonstrates that SEMS placement as a bridge to surgery results in:
- Higher mortality and morbidity
- Lower R0 resection rates
- Increased stent migration (29.9% of patients)
- Shorter time to recurrence and worse overall survival 1
Instead, use enteral feeding tubes (nasogastric or percutaneous) for nutritional support in malnourished patients 1. However, be aware that percutaneous endoscopic gastrostomy (PEG) carries risks of abdominal wall tumor seeding and can complicate subsequent gastric conduit formation 1.
For Non-Resectable Disease
Consider either SEMS insertion or brachytherapy as sole therapy or in combination 1. When placing SEMS:
- Use fully covered or partially covered SEMS, NOT uncovered SEMS
- Consider stent-anchoring/fixation methods to reduce migration 1
- Avoid laser therapy or photodynamic therapy due to lack of evidence for better outcomes 1
Gastric Outlet Obstruction
Decision Algorithm Based on Life Expectancy and Functional Status
For patients with life expectancy >2 months, good functional status, and surgical fitness: surgical gastrojejunostomy is the preferred intervention 1.
- Use laparoscopic approach over open approach due to lower blood loss and shorter hospital stay 1
For patients who are NOT candidates for gastrojejunostomy (surgical or EUS-guided): insert an enteral stent 1.
Critical contraindications for enteral stents 1:
- Multiple luminal obstructions
- Severely impaired gastric motility
In these scenarios, place a venting gastrostomy instead 1.
EUS-guided gastrojejunostomy is an acceptable alternative to surgical gastrojejunostomy and enteral stenting, depending on endoscopist experience 1. Note that no FDA-approved devices currently exist specifically for EUS-guided gastrojejunostomy 1.
Malignant Colonic Obstruction
For Resectable Disease
SEMS placement is a reasonable choice as a "bridge to surgery" to allow for one-stage, elective resection 1. This applies to both distal and proximal (right-sided) obstructions 1.
For Non-Resectable Disease
Either SEMS placement or diverting colostomy are reasonable choices based on patient goals and functional status 1.
SEMS is particularly reasonable for:
- Proximal/right-sided obstructions (both bridge to surgery and palliative settings) 1
- Extracolonic malignancy patients not suitable for surgery, though be aware of:
- More technically challenging placement
- More variable clinical success rates
- Higher complication rates including stent migration 1
Medical Management for Inoperable Obstruction
For patients at end of life or with inoperable obstruction, prioritize symptom control 2:
Pharmacologic Interventions
Consider corticosteroids and octreotide for malignant bowel obstruction 2. Despite their role in symptom management, these medications are significantly underutilized (steroids 22.2%, octreotide 11.1% in recent data) 3.
For diarrhea/bloating:
- Empirical trial of rifaximin for 1 week
- Bile acid sequestrant for 10 days
- Pancreatic enzyme replacement therapy (PERT) for 10 days 2
Nasogastric Tube Placement
Only insert a nasogastric tube if the patient specifically wants to try this AND other measures to relieve obstructive symptoms have failed 2.
Venting Gastrostomy
Palliative venting gastrostomy can relieve symptoms and improve quality of life in the absence of extensive peritoneal or gastric serosal disease 2. This is particularly useful when other decompression methods have failed.
Parenteral Nutrition
If the patient has good performance status and parenteral nutrition is a possibility, seek advice from a gastroenterologist-led nutrition team at the earliest opportunity 2. This is especially relevant for patients who are not actively dying and have good functional status (ASA grade <3), where reversal of enteral failure might make therapeutic options available 2.
Critical Prognostic Factors
Sepsis at admission is associated with 100% mortality 3, reinforcing the need for early infection management.
Higher BMI correlates positively with survival in patients with inoperable malignant bowel obstruction 3.
Elevated inflammatory markers (CRP), steroid use, NG tube placement, and parenteral hydration are associated with longer hospital stays, though these did not reach statistical significance in recent studies 3.
Common Pitfalls to Avoid
Do not place esophageal SEMS in resectable patients without multidisciplinary review—this worsens surgical outcomes 1
Do not use enteral stents in patients with multiple luminal obstructions or severely impaired gastric motility—they provide limited benefit 1
Do not assume all bleeding in cancer patients is from the tumor—more than one-third have non-malignant treatable causes (varices, peptic ulcers, angioectasia) 2
Do not delay early palliative care referral—acute hospital admission should trigger referral 2
Avoid unnecessary hospital attendance in the last phase of life—patients frequently have poor experiences with no clear benefits 2